Stay updated on Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.

Latest updates to the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page
- Check3 days agoChange DetectedLocations section updated to include New York and Wisconsin as study sites. Location subsections were reorganized under a new Locations header.SummaryDifference0.3%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now shows Revision: v3.3.2 instead of v3.3.1; there are no visible changes to the study details or layout.SummaryDifference0.1%

- Check32 days agoChange DetectedFooter revision label updated from v3.2.0 to v3.3.1. The change does not modify study details, eligibility criteria, or results information.SummaryDifference0.1%

- Check39 days agoChange DetectedRemoved a general government funding/operating status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check46 days agoChange DetectedThe related topics Prostate cancer and MedlinePlus Genetics were removed from the page. The primary study details, design, and locations remain unchanged.SummaryDifference0.2%

- Check54 days agoChange DetectedAdded 'Prostate cancer' and 'related topics: MedlinePlus Genetics' to the page's related topics. This is a minor metadata update that does not alter core trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

Stay in the know with updates to Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.